Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

NCT07153770 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
MET Exon 14 Mutation
MET Activating Mutation

Interventions

DRUG: Bozitinib

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China